메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

Chengdu CATANIA's Tower 2 Debuts Globally: A 222-Meter-High Sky Residence Redefining Global Luxury Living.

CHENGDU, China, Oct. 20, 2025 -- A news report from CNS: Recently, a wave of discerning homebuyers from different cities has been converging on Chengdu CATANIA. International elites from New York, London, Tokyo, Singapore, Hong Kong, Vancouver, and other world-class major cities have found a common ground in Chengdu. The global acclaim for Chengdu CATANIA goes far beyond a simple purchase. It is an affirmation of its international standing. This recognition stems from its core advantages—an unrivaled location, top-tier amenities, and a deeply integrated art gene. These q
- 김장윤(JASON KIM) 기자
- 2025-10-20 13:56
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer

SUZHOU, China, Oct. 20, 2025 -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted another breakthrough therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the indication of monotherapy for the treatment of HER2-positive advanced colorectal cancer (CRC) in patients who have failed prior treatments with oxaliplatin, fluorouracil and irino
- 김갑성 기자
- 2025-10-20 13:21
Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025

SUZHOU, China, Oct. 20, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ovarian cancer (OC) and HER2-positive metastatic colorectal cancer (mCRC), along with the confirmatory study design of the phase III study of JSKN003 versus physician's choice of chemotherapy in platinum-resistant ovarian cancer (PROC) were presented as posters at the 2025 European Society for Medical Oncology Congress (ESMO Congress 2025) from October 17 to 21, 2025,
- 김갑성 기자
- 2025-10-20 13:15
1664 ANNOUNCES FIRST-EVER ASIA-WIDE ARTIST COLLABORATION WITH FRENCH ARTIST CAMILLE WALALA

A Joyful, Design-led Partnership to Celebrate the Festive Season HONG KONG, Oct. 20, 2025 -- This festive season, 1664 is excited to announce its first-ever festive artist collaboration across Hong Kong, mainland China, Singapore, Malaysia, and Vietnam with celebrated French artist Camille Walala. Bringing a modern twist to the traditional holiday season that encapsulates Christmas and Lunar New Year, 1664 will be introducing limited-edition designs and upbeat experiences from October 2025 onwards. This partnership exemplifies Carlsberg Group's strategy to transform convivial m
- 황정호 기자
- 2025-10-20 12:00
Nongshim Shin Ramyun Light Ups New York Times Square with 'KPop Demon Hunters'

[ 메디채널 김장윤(JASON KIM) 기자 ] - Global campaign celebrates the U.S. debut of the movie-inspired collaboration package - NEW YORK, Oct. 20, 2025 -- Nongshim carried out a global campaign at New York Times Square to celebrate the launch of Shin Ramyun in collaboration with Netflix's hit animated film 'KPop Demon Hunters'. As known for "The Crossroads of the World" and attracting over 450,000 visitors daily, Times Square served as the stage for global consumers to directly taste and enjoy the Shin Ramyun brand through a variety of interactive activities that seamlessly connected
- 김장윤(JASON KIM) 기자
- 2025-10-20 11:23
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM

CHENGDU, China, Oct. 20, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in EGFR-mutated non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) was presented as an oral report by Professor Li Z
- 김갑성 기자
- 2025-10-20 10:36
Grand Opening of the 2025 Sustainable Global Leaders Conference: Kevin Kelly and the Turing Award Winner Share AI Frontiers, Business Leaders Discuss Sustainable Development

SHANGHAI, Oct. 20, 2025 -- Approved by the State Council, the 2025 Sustainable Global Leaders Conference opened on October 16 in Huangpu District, Shanghai. Centered around the theme "Joining Hands to Address Challenges: Global Action, Innovation, and Sustainable Growth," the Conference brings together global wisdom and strength to explore new pathways for sustainable development, injecting powerful "Chinese dynamism" into global sustainable governance. The Conference is jointly organized by the World Green Design Organization (WGDO) and Sina Group, co-organ
- 황정호 기자
- 2025-10-20 10:20
Xinhua Silk Road: Financial Street Forum annual conference to be held on Oct. 27-30 in Beijing

BEIJING, Oct. 20, 2025 -- The annual conference of Financial Street Forum 2025 will be held on October 27-30 in Beijing. Over 400 delegates from more than 30 countries and regions will join the four-day conference, introduced by an official of the organizing committee of the forum at a press briefing here on Friday. This year's conference will include a main forum and several parallel forums, discussing topics on international and domestic economic situation and financial supervision, international financial governance and cooperation, high-quality financial opening up and how t
- 황정호 기자
- 2025-10-20 09:35
Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability

SHANGHAI and HONG KONG, Oct. 20, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the latest results from the ongoing Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]), were presented in a Poster Presentation at the European Society for Medical Oncology Congress 2025 (ESMO 2025) in Berlin, Germany.&nbs
- 김갑성 기자
- 2025-10-20 09:00
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025

SHANGHAI, Oct. 20, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for pancreatic cancer (PC) adjuvant therapy in China (CT041-ST-05, NCT05911217) has been presented in poster session at European Society for Medical Oncology (ESMO) Congress 2025. The poster was titled "Adjuvant Therap
- 김갑성 기자
- 2025-10-20 08:15

이전

41 42 43 44 45 46 47 48 49 50

많이 본 기사

최근기사

2025-10-29_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 29일 19시 40분